How to Buy Tarsus Pharmaceuticals Stock
Tarsus Pharmaceuticals Inc
Tarsus Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions.
Tarsus Pharmaceuticals stock last closed at $32.76, down 2.82% from the previous day, and has increased 124.08% in one year. It has overperformed other stocks in the Biotechnology industry by 1.48 percentage points. Tarsus Pharmaceuticals stock is currently +160.62% from its 52-week low of $12.57, and -18.91% from its 52-week high of $40.40.
As of Apr 24, 2024, there are 34.22M TARS shares outstanding. The market cap of TARS is $1.12B. In the last 24 hours, 317,495 TARS shares were traded.
How to Buy Tarsus Pharmaceuticals Stock
Not sure how to invest in Tarsus Pharmaceuticals stock? Here's how.
- Choose where to buy Tarsus Pharmaceuticals stock: You need to pick a stock brokerage, but don't worry - we've tested dozens of online brokerages and apps to help you figure out where to buy Tarsus Pharmaceuticals stock.
- Create a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Fund your brokerage account: Choose your method of payment and add your info.
- Research Tarsus Pharmaceuticals stock: The Tarsus Pharmaceuticals ticker symbol is TARS. Is Tarsus Pharmaceuticals stock a good investment? Should you buy shares of TARS? How do TARS's underlying business fundamentals look? Do top analysts think Tarsus Pharmaceuticals is a good buy? Why has TARS's stock price moved recently? (Hint: Our stock research tools can help you decide if TARS is a good stock to buy).
- Make your TARS buy order: Decide if you will purchase TARS shares at the current market price or use a limit order to purchase TARS shares at a particular price.
- Keep tabs on your TARS investment: Create a watchlist to keep tabs on your position in Tarsus Pharmaceuticals stock.
Step 1: Choose where to buy Tarsus Pharmaceuticals stock
You need an online brokerage account in order to access the NASDAQ market and buy TARS shares.
Our favorite brokerage: eToro
We believe that eToro is the best online stock brokerage. eToro gives you:
- You can invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to world financial markets: From Tech to Financial Services, New York to London — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro offers a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by signing up for an account with eToro today.
Open eToro AccountStep 2: Create a brokerage account
Now that you've chosen your brokerage, you'll need to fill out some personal info so you can invest in TARS today.
How to Set Up a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal info to start your new trading account.
- Send your application by clicking the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you have finished signing up on app for stock, your next step is to transfer the money for your investment:
Watch the tutorial below if you need help depositing funds into your investment account.
Step 4: Research Tarsus Pharmaceuticals stock
Once you have figured out the best place to buy Tarsus Pharmaceuticals stock, it's crucial to evaluate their stock before you buy, so you truly comprehend the risk as well as the opportunity.
Tarsus Pharmaceuticals shares data
TARS Overview
WallStreetZen was created to help average investors perform better fundamental analysis.
You can view all of the due diligence checks on TARS's stock page.
Is TARS stock undervalued?
Analysts use many financial metrics, analyses, models, and charts to gauge TARS's true value.
Using relative valuations measures:
- TARS could be undervalued based on its P/B ratio of 5.69x, relative to Biotechnology industry P/B ratio of 5.86x
You can do additional valuation analysis on TARS's stock here.
TARS Financial Health
Pros:
- TARS has cash burn of 122995000. It has sufficient cash and short-term investments to cover this for at least one year.
- Total TARS debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the TARS balance sheet.
- TARS has a low debt to equity ratio of 0.35.
- There are more short-term assets than long-term liabilities on the TARS balance sheet.
Cons:
- TARS has $227.44M in cash and short term investments. This is not sufficient to cover its annual cash burn of $123.00M.
- TARS profit margin has gone down from -240.5% to -778.9% in the past year.
Is it a good time to buy TARS stock, according to Wall Street analysts?
Out of 5 Wall Street analysts who monitor TARS, the consensus analyst rating on Tarsus Pharmaceuticals is a Buy
It's important to keep in mind that analyst ratings are not stock recommendations, nor are they financial advice.
You can dig deeper into what analysts are projecting on the Tarsus Pharmaceuticals stock forecast page.
TARS Technical Indicators
How are TARS Revenues/Earnings doing?
Last year, TARS revenue was $17.45M. In the past 2 year, TARS's revenue has gone up by -44.69% per year. This was slower than the Biotechnology industry average of 28.91%.
Dive into TARS's earnings and revenue performance here.
Latest Insiders Trades at TARS
In the last 12 months, executives and large shareholders at TARS have sold more shares than they have bought.
Bobak R. Azamian, PresidentCEO and Board Chair of TARS, was the latest TARS insider to sell. They sold $318,699.00 worth of TARS shares on Mar 18, 2024.
Get more info about who owns TARS stock here.
Does TARS provide a stable income stream?
No, Tarsus Pharmaceuticals doesn't provide an income stream by paying out dividends.
What others are saying about TARS
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other community members have to say.
Step 5: Make your TARS buy order
There are two main types of orders:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are usually the best for newer investors. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to ensure you're buying or selling at a specific dollar amount limit, use a limit order.
Press the Open button and your broker will place your order.
If you want more help investing in stocks on eToro, click the helpful video below:
Step 6: Keep tabs on your TARS investment
Now that you own some shares in TARS, you'll want to stay up-to-date on your stock purchase.
Create a watchlist to track the latest developments regarding your TARS stock.
TARS Feed
How to Buy Stock in Tarsus Pharmaceuticals
To summarize, here are the 6 steps you need to take to buy Tarsus Pharmaceuticals stock right now:
- Choose where to buy Tarsus Pharmaceuticals stock
- Create a brokerage account
- Fund your brokerage account
- Research Tarsus Pharmaceuticals stock
- Make your TARS buy order
- Keep tabs on your TARS investment
If you need a place to buy stocks, eToro is our favorite option.
Get Started with eToro TodayIf you would like to get updates on your new investment in Tarsus Pharmaceuticals, add TARS to your watchlist by clicking the button below.
More Stock Buying Guides You May Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.